In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy (MEC).

Inclusion Criteria:

• Patient has been diagnosed with histologically or cytologically confirmed solid cancer
• Starting with first cycle of chemotherapy of moderate emetogenic risk, which does not include a combination of anthracycline plus cyclophosphamide
• Age ≥ 18
• WHO ≤ 1
• Patient is able to understand and speak Dutch

Exclusion Criteria:

• Patient with nausea and/or vomiting in 48 hours before start of chemotherapy treatment
• Patient submitted to concomitant radiotherapy or submitted to radiotherapy 15 days before start of chemotherapy or planned to receive radiotherapy during 8 days after administration of chemotherapy
• Patient with concomitant severe comorbidy, such as: o Intestinal obstruction o Active peptic ulcer o Hypercalcemia o Uncontrolled diabetes mellitus o Pheochromocytoma o Tardive dyskinesia o Epilepsia o Active infective diseases o Brain - or leptomeningeal metastases o Psychiatrical disorders o Parkinsonism
• Current use of corticosteroids (similar to prednisone ≥ 10 milligrams per day)
• Current alcohol abuse
• Pregnancy